Hep C Virus - Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program

Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program
[Press Release] PR Newswire via Yahoo! Finance - Jan 18 4:00 AM
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin Anti-Viral for the treatment of chronic hepatitis C virus infection .Save to My Web